欧文原著
1. Conditional knockout of the leptin receptor in the colonic epithelium
revealed the local effects of leptin receptor signaling in the progression
of colonic tumors in mice.
Higurashi T, Endo H, Uchiyama T, Uchiyama S, Yamada E, Ohkubo H, Sakai
E, Takahashi H, Maeda S, Wada K,
Natsumeda Y, Hippo Y, Nakajima A, Nakagama H.
Carcinogenesis. 35:2134-41, 2014
2. Protective mucosal immunity mediated by epithelial CD1d and IL-10.
Olszak T, Neves JF, Dowds CM, Baker K, Glickman J, Davidson NO, Lin CS,
Jobin C, Brand S, Sotlar K, Wada K,
Katayama K, Nakajima A, Mizuguchi H, Kawasaki K, Nagata K, Müller W,
Snapper SB, Schreiber S, Kaser A,
Zeissig S, Blumberg RS.
Nature. 509:497-502, 2014
3. Expression of fatty acid binding protein 4 is involved in the cell growth
of oral squamous cell carcinoma.
Lee D, Wada K, Taniguchi Y, Al-Shareef H, Masuda T, Usami Y, Aikawa T, Okura M, Kogo
M.
Oncology Reports 31: 1116-1120, 2014
4. Critical role of leukotriene B4 receptor signaling in mouse 3T3-L1 preadipocyte
differentiation.
Hirata K, Wada K, Murata Y, Nakajima A, Yamashiro T, Kamisaki Y.
Lipids in Health and Disease. 12:122, 2013
5. Oral choline tolerance test as a novel noninvasive method for predicting
nonalcoholic steatohepatitis.
Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y, Shinohara
Y, Sekino Y, Mawatari H, Nozaki Y,
Kirikoshi H, Taguri M, Toshima G, Takahashi J, Saito S, Wada K, Nakajima A.
Journal of Gastroenterology. 49:295-304, 2014
6. Soluble CD14 levels reflect liver inflammation in patients with nonalcoholic
steatohepatitis.
Ogawa Y, Imajo K, Yoneda M, Kessoku T, Tomeno W, Shinohara Y, Kato S,
Mawatari H, Nozaki Y, Fujita K,
Kirikoshi H, Maeda S, Saito S, Wada K, Nakajima A.
PLoS One. 8(6):e65211, 2013
7. Peroxisome proliferator-activated receptor gamma exacerbates Concanavalin
A-induced liver injury via suppressing
the translocation of NF-kB into the nucleus.
Ogawa Y, Yoneda M, Tomeno W, Imajo K, Shinohara Y, Fujita K, Shibata
W, Kirikoshi H, Saito S, Wada K,
Maeda S, Nakajima A.
PPAR Research. 2012:940384, 2012
8. Role of leukotriene B4 receptor signaling in human preadipocyte differentiation.
Hirata K, Katayama K, Nakajima A, Takada K, Kamisaki Y, Wada K.
Biochemical and Biophysical Research Communications. 429:197-203, 2012
9. Plasma free choline is a novel non-invasive biomarker for early-stage
non-alcoholic steatohepatitis: A multi-center
validation study.
Imajo K, Fujita K, Yoneda M, Shinohara Y, Suzuki K, Mawatari H, Takahashi
J, Nozaki Y, Sumida Y, Kirikoshi H,
Saito S, Nakamuta M, Matsuhashi N, Wada K, Nakajima A.
Hepatology Research. 42: 757-766, 2012
10. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic
steatohepatitis is regulated by
leptin-mediated signaling.
Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S,
Mawatari H, Shibata W, Kitani H,
Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A.
Cell Metabolism. 16: 44-54, 2012
11. Infection of specific strains of Streptococcus mutans, oral bacteria,
confers a risk of ulcerative colitis.
Kojima A, Nakano K, Wada K, Takahashi H, Katayama K, Yoneda M, Higurashi T, Nomura R, Hokamura K,
Muranaka Y, Matsuhashi N, Umemura K, Kamisaki Y, Nakajima A, Ooshima
T.
Scientific Reports 2:332, 2012 .
12. Differential expression of aquaporin 5 and aquaporin 3 in squamous
cell carcinoma and adenoid cystic carcinoma.
Ishimoto S, Wada K, Usami Y, Tanaka N, Aikawa T, Okura M, Nakajima A, Kogo M, Kamisaki Y.
International Journal of Oncology. 41: 67-75, 2012.
13. Involvement of a periodontal pathogen, Porphyromonas gingivalis on
the pathogenesis of non-alcoholic fatty liver disease.
Yoneda M, Naka S, Nakano K, Wada K, Endo H, Mawatari H, Imajo K, Nomura R, Hokamura K, Ono M, Murata S,
Tohnai I, Sumida Y, Shima T, Kuboniwa M, Umemura K, Kamisaki Y, AmanoA,
OkanoueT, OoshimaT, Nakajima A.
BMC Gastroenterology. 12: 16, 2012.
14. Role of endothelin receptor signaling in squamous cell carcinoma.
Ishimoto S, Wada K, Tanaka N, Yamanishi T, Ishihama K, Aikawa T, Okura M, Nakajima A, Kogo
M, Kamisaki Y.
International Journal of Oncology. 40: 1011-1019, 2012.
15. The collagen-binding protein of Streptococcus mutans is involved in
hemorrhagic stroke.
Nakano K, Hokamura K, Taniguchi N, Wada K, Kudo C, Nomura R, Kojima A, Naka S, Muranaka Y, Thura M,
Nakajima A, Masuda K, Nakagawa I, Speziale P, Shimada N, Amano A, Kamisaki
Y, Tanaka T, Umemura K, Ooshima T.
Nature Communications. 2: 485, 2011.
16. Liver abscess caused by periodontal bacterial infection with Fusobacterium
necrophorum. Case Report
Yoneda M, Kato S, Mawatari H, Kirikoshi H, Imajo K, Fujita K, Endo H,
Takahashi H, Inamori M, Kobayashi N,
Kubota K, Saito S, Tohnai I, Watanuki K, Wada K, Maeda S, Nakajima A.
Hepatology Research. 41: 194-196, 2011.
17. Critical role of aquaporin 3 on growth of human esophageal and oral
squamous cell carcinoma.
Kusayama M, Wada K, Nagata M, Ishimoto S, Takahashi H, Yoneda M, Nakajima A, Okura M, Kogo
M, Kamisaki Y.
Cancer Science. 102: 1128-1136, 2011.
18. Leptin receptor is involved in STAT3 activation in human colorectal
adenoma.
Uchiyama T, Takahashi H, Sugiyama M, Sakai E, Hosono K, Endo H, Yoneda
K, Yoneda M, Inamori M,
Nagashima Y, Inayama Y, Wada K, Nakajima A.
Cancer Science. 102: 367-372, 2011.
19. Leptin acts as a growth factor for colorectal tumours at stages subsequent
to tumour initiation in murine colon
carcinogenesis.
Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, Nakajima
N, Wada K, Takeda K,
Nakagama H, Nakajima A.
Gut. 60:1363-1371, 2011.
20. Role of the long form leptin receptor and of the STAT3 signaling pathway
in colorectal cancer progression.
Uchiyama T, Takahashi H, Endo H, Sugiyama M, Sakai E, Hosono K, Nagashima
Y, Inayama Y, Wada K, Hippo Y,
Nakajima A.
International Journal of Oncology. 39: 935-940, 2011.
21. Serum nitric oxide metabolite as a biomarker of visceral fat accumulation:
clinical significance of measurement for
nitrate/nitrite.
Fujita K, Wada K, Nozaki Y, Yoneda M, Endo H, Takahashi H, Kirikoshi H, Inamori M, Saito
S, Nakajima A.
Medical Science Monitor. 17: CR123-131, 2011.
22. Characterization of aortic aneurysms in cardiovascular disease patients
harboring Porphyromonas gingivalis.
Nakano K, Wada K, Nomura R, Nemoto H, Inaba H, Kojima A, Naka S, Hokamura K, MukaiT, Nakajima
A,
Umemura K, Kamisaki Y, Yoshioka H, Taniguchi K, Amano A, Ooshima T.
Oral Diseases. 17: 370-378, 2011.
23. Molecular detection of human periodontal pathogens in oral swab specimens
from dogs in Japan.
Kato Y, Shirai M, Murakami M, Mizusawa T, Hagimoto A, Wada K, Nomura R, Nakano K, Ooshima T, Asai F.
Journal of Veterinary Dentistry. 28: 84-89, 2011.
24. Distribution of oral streptococci highly resistant toamoxicillin in
dental plaque specimens from Japanese children
andadolescents.
Nemoto H, Nakano K, Masuda K, Wada K, Ardin AC, Nomura R, Ooshima T.
Journal of Medical Microbiology. 60: 1853-1859, 2011.
25. Molecular analysis of aortic intimal hyperplasia caused by Porphyromonas
gingivalis infection in mice
with endothelial damage.
Hokamura K, Inaba H, Nakano K, Nomura R, Yoshioka H, Taniguchi K, Ooshima
T, Wada K, Amano A, Umemura K.
Journal of Periodontal Research. 45: 337-344, 2010.
26. Nitric oxide plays a crucial role in the development/progression of
nonalcoholic steatohepatitis (NASH)
in the choline-deficient, l-amino acid-defined (CDAA) diet-fed rat model.
Fujita K, Yoneda M, Nozaki Y, Wada K, Takahashi H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y,
Maeyama S, Nakajima A.
Alcoholism-Clinical and Experimental Research. 34: S18-24, 2010 .
27. cis9, trans11-conjugated linoleic acid differentiates mouse 3T3-L1
preadipocytes into mature small adipocytes
through induction of peroxisome proliferator-activated receptor gamma.
Sakuma S, Nishioka Y, Imanishi R, Nishikawa K, Sakamoto H, Fujisawa J,
Wada K, Kamisaki Y, Fujimoto Y.
Journal of Clinical Biochemistry and Nutrition. 47: 167-173, 2010.
28. Dysfunctional VLDL synthesis and release is a key factor in non-alcoholic
steatohepatitis (NASH) pathogenesis.
Fujita K, Nozaki Y, Wada K, Yoneda M, Fujimoto Y, Fujitake M, Endo H, Takahashi H, Inamori M, Kirikoshi
H,
Kubota K, Saito S, Nakajima A.
Hepatology. 50: 772-780, 2009 .
29. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic
fatty liver disease.
Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S,
Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
Journal of Hepatology. 51: 548-556, 2009 .
30. Association of visceral fat accumulation and plasma adiponection with
rectal dysplastic aberrant crypt foci
in a clinical population.
Takahashi H, Takayama T, Yoneda K, Endo H, Iida H, Sugiyama M, Fujita
K, Yoneda M, Inamori M, Abe Y,
Saito S, Wada K, Nakagama H, Nakajima A.
Cancer Science. 100: 29-32, 2009 .
31. Upregulation of S100 calcium-binding protein A9 is required for induction
of smooth muscle cell proliferation
by a periodontal pathogen.
Inaba H, Hokamura K, Nakano K, Nomura R, Katayama K, Nakajima A, Yoshioka
H, Taniguchi K, Kamisaki Y,
Ooshima T, Umemura K, Murad F, Wada K.
FEBS Letters. 583: 128-134, 2009 .
32. Role of myeloid cell leukemia-1 on cell growth of squamous cell carcinoma.
Nagata M, Wada K, Nakajima A, Kusayama M, MasudaT, IidaS, OkuraM, KogoM, Kamisaki Y.
Journal of Pharmacological Sciences. 110: 344-353, 2009 .
33. Involvement of JNK pathway in the promotion of the early stage of colorectal
carcinogenesis under high-fat dietary
condition.
Endo H, Hosono K, Fujisawa T, Takahashi H, Sugiyama M, Yoneda K, Nozaki
Y, Fujita K, Yoneda M, Inamori M,
Wada K, Nakagama H, Nakajima A.
Gut. 58: 1637-1643, 2009 .
34. Influence of iNOS polymorphisms in Japanese patients with nonalcoholic
fatty liver disease.
Yoneda M, Hotta K, Nozaki Y, Endo H, Tomeno W, Watanabe S, Hosono K,
Mawatari H, Iida H, Fujita K,
Takahashi H, Kirikoshi H, Kobayashi H, Inamori M, Kubota K, Shimamura
T, Saito S, Maeyama S, Wada K,
Nakajima A.
Hepatology Research. 39: 963-971, 2009.
35. Association between angiotensin II type1receptor polymorphisms and
the occurrence of nonalcoholic fatty liver disease.
Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H,
Kato S, Fujita K, Takahashi H,
Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama
S, Wada K, Nakajima A.
Liver International. 29: 1078-1085, 2009.
36. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR
pathway.
Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y,
Fujita K, Yoneda M, Wada K,
Nakagama H, Nakajima A.
International Journal of Oncology. 34: 339-344, 2009 .
37. Adiponectin suppresses colorectal carcinogenesis under the high-fat
diet condition.
Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori
M, Nakajima N, Watanabe M,
Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A.
Gut. 57: 1531-1538, 2008 .
38. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic
fatty liver disease (NAFLD).
Yoneda M, Nozaki Y, Endo H, Mawatari H, Fujita K, Yoneda K, Takahashi H,
Kirikoshi H, Inamori M, Abe Y,
Kubota K, Saito S, Maeyama S, Wada K, Hotta K, Nakajima A.
BMC Gastroenterology. 8: Article No. 27; doi: 10.1186/1471-230X-8-27, 2008.
39. Peroxisome proliferator-activated receptor gamma suppresses colonic
epithelial cell turnover
and colon carcinogenesis through inhibition of the beta-catenin/T cell
factor (TCF) pathway.
Fujisawa T, Nakajima A, Fujisawa N, Takahashi H, Tomimoto A, Yonemitsu
K, Nakajima N, Wada K, Kubota N,
Terauchi Y, Kadowaki T, Nakagama H, Blumberg RS.
Journal of Pharmacological Sciences. 106: 627-638, 2008.
40. Metoformin suppresses intestinal polyp growth in ACP (Min-/+) Mice.
Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima
N, Nagashima Y, Wada K,
Nakagama H, Nakajima A.
Cancer Science. 99: 2136-2141, 2008.
41. Inhibition of peroxisome proliferator-activated receptor gamma promotes
tumorigenesis through activation of
beta-catenin/T cell factor (TCF) pathway in the mouse intestine.
Fujisawa T, Sugiyama M, Tomimoto A, Wada K, Endo H, Takahashi H, Yoneda K, Yoneda M, Inamori M, Saito S,
Terauchi Y, Kadowaki T, Tsuchiya N, Nakagama H, Nakajima A.
Journal of Pharmacological Sciences. 108: 535-544, 2008.
42. Activation of peroxisome proliferator-activated receptor γ suppresses
mast cell maturation involved in allergic diseases.
Tachibana M, Wada K, Katayama K, Kamisaki Y, Maeyama K, Kadowaki T, Blumberg RS, Nakajima
A.
Allergy. 63: 1136-1147, 2008.
43. Effectiveness of antiplatelet drugs against experimental non-alcoholic
fatty liver disease.
Fujita K, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Iwasaki T, Inamori M, Abe Y, Kobayashi
N,
Kirikoshi H, Kubota K, Saito S, Nagashima Y, Nakajima A.
Gut. 57: 1583-1591, 2008.
44. Comparison of the protective effect of N-acetylcysteine by different
treatments on rat myocardial
ischemia-reperfusion injury.
Abe M, Takiguchi Y, Ichimura S, Tuchiya K, Wada K.
Journal of Pharmacological Sciences. 106: 571-577, 2008.
45. Expression of adiponectin receptors, AdipoR1 and AdipoR2, in normal
colon epithelium and colon cancer tissue.
Yoneda K, Tomimoto A, Endo H, Iida H, Sugiyama M, Takahashi H, Mawatari
H, Nozaki Y, Fujita K, Yoneda M,
Inamori M, Nakajima N, Wada K, Nagashima Y, Nakagama H, Uozaki H, Hukayama M, Nakajima A.
Oncology Reports. 20: 479-483, 2008.
46. Different effect of acute treatment with rosiglitazone on rat myocardial
ischemia/reperfusion injury by administration
method.
Abe M, Takiguchi Y, Ichimura S, Kaji S, Tuchiya K, Wada K.
European Journal of Pharmacology. 589: 215-219, 2008.
47. Inhibition of Peroxisome Proliferator-activated receptor gamma activity
suppresses pancreatic cancer cell motility.
Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, Ikeda I, Hosono
K, Endo H, Yoneda K, Iida H,
Nakajima N, Wada K, Nagashima Y, Nakagama H.
Cancer Science. 99: 1892-1900, 2008.
48. Gene Expression Profiling of Nonalcoholic Steatohepatitis (NASH) by
Gene Set Enrichment Analysis (GSEA).
Yoneda M, Endo H, Mawatari H, Nozaki Y, Fujita K, Akiyama T, Higurashi
T, Uchiyama T, Yoneda K,
Takahashi H, Kirikoshi H, Inamori M, Abe Y, Kubota K, Saito S, Kobayashi
N, Yamaguchi N, Maeyama S,
Yamamoto S, Tsutsumi S, Aburatani H, Wada K, HottaK, Nakajima A.
Hepatology Research. 38: 1204-1212, 2008.
49. 5-Aminosalicylic acid given in the remission stage of colitis suppresses
colitis-associated cancer in a mouse colitis model.
Ikeda I, Tomimoto A, Wada K, Fujisawa T, Fujita K, Yonemitsu K, Nozaki Y, Endo H, Takahashi H, Yoneda
M,
Inamori M, Kubota K, Saito S, Nakagama H, Nakajima A.
Clinical Cancer Research. 13: 6527-6531, 2007.
50. Telmisartan, an angiotensin II type 1 receptor blocker, controls progress
of nonalcoholic steatohepatitis in rats.
Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Maeyama S,
Saito S,
Iwasaki T, Terauchi Y, Nakajima A.
Digestive Diseases and Sciences. 52: 3455-3464, 2007.
51. Blockade of leukotriene B4 signaling pathway induces apoptosis and
suppresses cell proliferation in colon cancer.
Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A.
Journal of Pharmacological Sciences. 103: 24-32, 2007.
52. Hypoadiponectinemia plays a crucial role in the development of nonalcoholic
fatty liver disease in patients with type 2
diabetes mellitus independent of visceral adipose tissue.
Yoneda M, Iwasaki T, Fujita K, Kirikoshi H, Inamori M, Nozaki Y, Maeyama
S, Wada K, Saito S, Terauchi Y,
Nakajima A.
Alcoholism-Clinical and Experimental Research. 31: S15-21, 2007.
53. Critical role of estrogen receptor on anoikis and invasion of squamous
cell carcinoma.
Ishida H, Wada K, Masuda T, Okura M, Kohama K, Nakajima A, Kamisaki Y.
Cancer Science. 98: 636-643, 2007.
54. Peroxosime proliferator-activated receptor gamma-mediated regulation
of neural stem cell proliferation and
differentiation.
Wada K, Nakajima A, Katayama K, Kudo C, Shibuya A, Kubota N, Terauchi Y, Tachibana
M, Miyoshi H,
Kamisaki Y, Mayumi T, Kadowaki T, Blumberg RS.
Journal of Biological Chemistry. 281: 12673-12681, 2006.
55. Leukotriene B4 and lipoxin A4 are regulatory signals for neural stem
cell proliferation and differentiation.
Wada K, Arita M, Nakajima A, Katayama K, Kudo C, Kamisaki Y, Serhan CN.
FASEB Journal. 20: 1785-1792, 2006.
56. Inhibition of PPARγ activity in esophageal carcinoma cells results
in a drastic decrease of invasive properties.
Takahashi H, Fujita K, Fujisawa T, Yonemitsu K, Tomimoto A, Yoneda M,
Masuda T, Schaefer K,
Saubermann LJ, Shimamura T, Saitoh S, Tachibana M, Wada K, Nakagama H, Nakajima A.
Cancer Science 97: 854-860, 2006.
57. Peroxisome proliferator-activated receptor gamma inhibition prevents
adhesion to the extracellular matrix
and induces anoikis in hepatocellular carcinoma cells.
Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Wolfe MM, Nakajima A, Saubermann LJ.
Cancer Research. 65: 2251-2259, 2005.
58. Critical role of peroxisome proliferator-activated receptor γ on anoikis
and invasion of squamous cell carcinoma.
Masuda T, Wada K, Nakajima A, Okura M, Kadowaki T, Kogo M, Kamisaki Y.
Clinical Cancer Research. 11: 4012-4021, 2005 .
59. Serum ferritin is associated with visceral fat area and subcutaneous
fat area.
Iwasaki T, Nakajima A, Yoneda M, Yamada, Mukasa K, Fujita K, Fujisawa
N, Wada K, Terauchi Y.
Diabetes Care. 28: 2486-2491, 2005.
60. Marked attenuation of production of collagen typeI from cardiac fibroblasts
by DHEA.
Iwasaki T, Mukasa K, Yoneda M, Ito S, Yamada Y, Mori Y, Fujisawa N,
Fujisawa T, Wada K, Sekihara H, Nakajima A.
American Journal of Physiology-Endocrinology and Metabolism. 288: E1222-1228, 2005.
61. Intestinal antiinflammatory effects of thiazolidenedione peroxisome
proliferator-activated receptor-γ ligands
on T helper type 1 chemokine regulation include nontranscriptional control
mechanisms.
Schaefer KL, Denevich S, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ.
Inflammatory Bowel Diseases. 11: 244-252, 2005.
62. Protective effect of endogenous PPARγ against acute gastric mucosal
lesions associated with ischemia-reperfusion.
Wada K, Nakajima A, Takahashi H, Yoneda M, Fujisawa N, Ohsawa E, Kadowaki T,
Kubota N, Terauchi Y,
Matsuhashi N, Saubermann LJ, Nakajima A, Blumberg RS.
American Journal of Physiology-Gastrointestinal and Liver Physiology. 287: G452-458, 2004.
63. Nonylphenol induces the death of neural stem cells due to activation
of the caspase cascade and regulation
of the cell cycle.
Kudo C, Wada K, Masuda T, Yonemura T, Shibuya A, Fujimoto Y, Nakajima A, Niwa H, Kamisaki
Y.
Journal of Neurochemistry. 88: 1416-1423, 2004.
64. RNA interfering approach for clarifying the PPARγ pathway using lentiviral
vector expressing short hairpin RNA.
Katayama K, Wada K, Miyoshi H, Ohashi K, Tachibana M, Furuki R, Mizuguchi H, Hayakawa T,
Nakajima A,
Kadowaki T, Tsutsumi Y, Nakagawa S, Kamisaki Y, Mayumi T.
FEBS Letters. 560: 178-182, 2004 .
65. A novel therapy for acute hepatitis utilizing Dehydroepiandrosterone
in the murine model of hepatitis.
Yoneda M, Wada K, Katayama K, Nakajima N, Iwasaki T, Osawa E, Mukasa K, Yamada Y, Blumberg
RS,
Sekihara H, Nakajima A.
Biochemical Pharmacology. 68: 2283-2289, 2004.
66. Peroxisome proliferator-activated receptor γ ligands suppress colon
carcinogenesis induced by azoxymethane in mice.
Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T, Matsuhashi N, Kadowaki T, Ochiai
M, S
ekihara H, Nakagama H.
Gastroenterology. 124: 361-367, 2003.
67. A novel PPARγ-gene therapy to control inflammation associated with
inflammatory bowel disease in a murine model.
Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R,
Kamisaki Y,
Blumberg RS, Mayumi T.
Gastroenterology. 124: 1315-1324, 2003 .
68. Diclofenac inhibits proliferation and differentiation of neural stem
cells.
Kudo C, Kori M, Matsuzaki K, Nakajima A, Shibuya A, Niwa H, Kamisaki
Y, Wada K.
Biochemical Pharmacology. 66: 289-295, 2003.
69. Role for complement in mediating intestinal nitric oxide synthase 2
and superoxide dismutase expression.
Montalto MC, Hart ML, Johdan JE, Wada K, Stahl GL.
American Journal of Physiology-Gastrointestinal and Liver Physiology. 285: G197-206, 2003.
70. PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator
expressions
in adjuvant-induced rheumatoid arthritis mice.
Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, Kadowaki T, Mayumi T, Yura
Y, Kamisaki Y.
European Journal of Pharmacology. 448: 231-238, 2002.
71. Nitration of PPARγ inhibits ligand-dependent translocation into the
nucleus in a macrophage-like cell line, RAW 264.
Shibuya A, Wada K, Nakajima A, Saeki M, Katayama K, Mayumi T, Kadowaki T, Niwa H, Kamisaki
Y.
FEBS Letters. 525: 43-47, 2002 .
72. Gene expression profile after peroxisome proliferator activator receptor-γ
ligand administration
in dextran sodium sulfate mice.
Nakajima A, Wada K, Katayama K, Saubermann LJ, Osawa E, Nagase H, Ueno N, Matsuhashi N, Aburatani
H.
Journal of Gastroenterology. 37: 62-66, 2002 .
73. Chemoprevention of precursors to colon cancer by dehydroepiandrosterone
(DHEA).
Osawa E, Nakajima A, Yoshida S, Omura M, Nagase H, Wada K, Matsuhashi N, Ochiai M, Nakagama H, Sekihara H.
Life Sciences. 70: 2623-2630, 2002 .
74. PPARγ agonist ligands stimulate a Th2 cytokine response and prevent
acute colitis.
Saubermann JL, Nakajima A, Wada K, Terauchi Y, Kadowaki T, Aburatani H, Matsuhashi N, Nagai R, Blumberg
RS.
Inflammatory Bowel Diseases. 8: 330-339, 2002.
75. Inhibition of complement C5 reduces local and remote organ injury following
intestinal ischemia-reperfusion: A new
therapeutic approach.
Wada K, Montalto MC, Stahl GL.
Gastroenterology. 120: 126-133, 2001.
76. Endogenous PPARγ mediates anti-inflammatory activity in a model of
ischemia-reperfusion injury.
Wada K, Nakajima A (#: equally contribution as first author to this work), Miki
H, Kubota N, Nakajima N,
Terauchi Y, Ohnishi S, Saubermann JL, Kadowaki T, Blumberg RS, Nagai
R, Matsuhashi N.
Gastroenterology. 120: 460-469, 2001.
77. Insulin-like growth factor-1 protects peroxynitrite-induced cell death
by preventing cytochrome c-induced
caspase-3 activation.
Saeki M, Maeda S, Wada K, Kamisaki Y.
Journal of Cellular Biochemistry. 84: 708-716, 2002.
78. Inosine monophosphate (IMP) and aspirin-triggered 15-epi-lipoxin A4
act in concert to regulate neutrophil trafficking:
Additive actions of two new endogenous anti-inflammatory mediators.
Wada K, Qiu F, Stahl GL, Serhan CN.
Stem Cells and Development. (旧: Journal of Hematotherapy and Stem Cell Research) 10: 75-79, 2001 .
79. Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulates transcriptional
corepressor NAB1 in human neutrophils.
Qiu F, Devchand P, Wada K, Serhan CN.
FASEB Journal. 15: 2736-2738, 2001 .
80. IMP and AMP deaminase in reperfusion injury down-regulates neutrophil
recruitment.
Wada K#, Qiu F# (#: equally contribution as first author to this work), Stahl
GL, Serhan CN.
Proceedings of the National Academy of Sciences of the United States of
America. 97: 4267-4272, 2000.
81. Direct measurement of nitric oxide release in gastric mucosa during
ischemia-reperfusion in the rat.
Wada K, Kamisaki Y, Okura T, Kanda G, Nakamoto K, Kishimoto Y, Ashida K, Itoh
T.
American Journal of Physiology-Gastrointestinal and Liver Physiology. 274: G465-G471, 1998 .
82. The role of endogenous acid in the development of acute gastric ulcer
induced by ischemia-reperfusion in the rat.
Nakamoto K, Wada K, Kitano M, Kishimoto Y, Ashida K, Kamisaki Y, Itoh T.
Life Sciences. 62: PL 63-69, 1998.
83. Levels of COX-1 and -2 mRNA expression at various stages of acute gastric
injury
induced by ischemia-reperfusion in rats.
Kishimoto Y, Wada K, Nakamoto K, Kawasaki H, Hasegawa J.
Archives of Biochemistry and Biophysics. 352: 153-157, 1998.
84. Effect of ischemia-reperfusion on contractile function of rat urinary
bladder: Possible role of nitric oxide.
Saito M, Wada K, Kamisaki Y, Miyagawa I.
Life Sciences. 62: PL 149-156, 1998.
85. An activity in rat tissues that modifies nitrotyrosine-containing proteins.
Kamisaki Y, Wada K, Bian K, Balabanli B, Davis K, Martin E, Behbod F, Lee YC, Murad F.
Proceedings of the National Academy of Sciences of the United States of
America. 95: 11584-11589, 1998.
86. Effect of plaunotol on gastric injury induced by ischemia-reperfusion
in rats.
Wada K, Kamisaki Y, Nakamoto K, Kishimoto Y, Ashida K, Itoh T.
Journal of Pharmacy and Pharmacology. 49: 903-907, 1997.
87. Effect of sucralfate on acute gastric mucosal injury and gastric ulcer
induced by ischemia-reperfusion in rats.
Wada K, Kamisaki Y, Kitano M, Kishimoto Y, Nakamoto K, Itoh T.
Pharmacology. 54: 57-63, 1997.
88. Substances in the aqueous fraction of cigarette smoke inhibit lipid
peroxidation in synaptosomes of rat cerebral cortex.
Kamisaki Y, Wada K, Nakamoto K, Kishimoto Y, Ashida K, Itoh T.
IUBMB Life (旧: Biochemistry & Molecular Biology International) 42: 1-10, 1997.
89. Lipopolysaccharide-induced increase in plasma nitrotyrosine concentrations
in rats.
Kamisaki Y, Wada K, Ataka M, Yamada Y, Nakamoto K, Ashida K, Kishimoto Y.
Biochimica et Biophysica Acta (Mol Cell Res). 1362: 24-28, 1997.
90. Effects of cimetidine on acute gastric mucosal injury induced by ischemia-reperfusion
in rats.
Kitano M, Wada K, Kamisaki Y, Nakamoto K, Kishimoto Y, Kawasaki H, Itoh T.
Pharmacology. 55: 154-164, 1997.
91. Effect of extract of Agkistrodon Blomhoffii on acute gastric mucosal
lesions induced by ischemia-reperfusion in rats.
Wada K, Kamisaki Y, Kitano M, Kishimoto Y, Nakamoto K, ShimizY, Nose M, Itoh
T.
Journal of Pharmacy and Pharmacology. 49: 227-228, 1997.
92. Loss of heterozygosity of the retinoblastoma gene in liver cirrosis
accompanying hepatocellular carcinoma.
Ashida K, Kishimoto Y, Nakamoto K, Wada K, Shiota G, Kamisaki Y, Itoh T, Kawasaki H.
Journal of Cancer Research and Clinical Oncology. 123: 489-495, 1997.
93. Quantitative analysis of cyclooxygenase-2 gene expression on acute
gastric injury
induced by ischemia-reperfusion in rats.
Kishimoto Y, Wada K, Nakamoto K, Ashida K, Kamisaki Y, Kawasaki H, Itoh T.
Life Sciences. 60: PL127-PL133, 1997.
94. Loss of the tumor suppressor p53 gene at liver cirrhotic stage in Japanese
patients with hepatocellular carcinoma.
Kishimoto Y, Shiota G, Kamisaki Y, Wada K, Nakamoto K, Kitano M, Yamawaki, Kotani M, Itoh T, Kawasaki H.
Oncology. 54: 304-310, 1997.
95. Inhibition by cigarette smoke of lipid peroxidation-induced neurotransmitter
release.
Kamisaki Y, Wada K, Nakamoto K, Kishimoto Y, Ashida K, Itoh T.
Life Sciences. 60: PL229-PL233, 1997.
96. Protective effect of acetaminophen against acute gastric mucosal lesions
induced by ischemia-reperfusion in rat.
Nakamoto K, Kamisaki Y, Wada K, Kawasaki H, Itoh T.
Pharmacology. 54: 203-210, 1997.
97. Effect of cystathionine as a scavenger of superoxide generated from
human leukocytes or derived from
xanthine oxidase in vitro.
Wada K, Kamisaki Y, Nakamoto K, Itoh T.
European Journal of Pharmacology. 296: 335-340, 1996.
98. A new gastric ulcer model induced by ischemia-reperfusion in the rat:
Role of leukocytes on ulceration in rat stomach.
Wada K, Kamisaki Y, Kitano M, Kishimoto Y, Nakamoto K, Itoh T.
Life Sciences. 59: PL295-PL301, 1996 .
99. Sensitive determination of nitrotyrosine in human plasma by isocratic
high-performance liquid chromatography.
Kamisaki Y, Wada K, Nakamoto K, Kishimoto Y, Kitano M, Itoh T.
Journal of Chromatography B-Analytical Technologies in the Biomedical and
Life Sciences. 685: 343-347, 1996.
100. Altered prostaglandin metabolism induced by angiotensin converting
enzyme inhibitors in
broncho-alveolar lavage fluid of the guinea-pig.
Umemura K, Wada K, Suzuki Y, Nishiyama H, Nakashima M.
Journal of Pharmacological Sciences. 72: 17-21, 1996.
101. Effects of cigarette smoke on nitric oxide-induced increase in cyclic
GMP in nerve terminals of rat cerebral cortex.
Kamisaki Y, Wada K, Nakamoto K, Kishimoto Y, Itoh T.
Brain Research. 42: 39-44, 1996 .
102. A chemiluminescent detection of superoxide radical produced by adherent
leukocytes to the subendothelium
following thrombolysis.: Studies with a photochemically induced thrombosis
model in the guinea pig femoral artery.
Wada K, Umemura K, Nishiyama H, Saniabadi AR, Takiguchi Y, Nakano M, Nakashima
M.
Atherosclerosis. 122: 217-224, 1996.
103. Impairment of phagocytic cell respiratory burst by ultraviolet A in
the presence of fluoroquinolone:
an oxygen dependent phototoxic damage to cell surface microvilli.
Saniabadi AR, Wada K, Umemura K, Sakuma S, NakashimaM.
Journal of Photochemistry and Photobiology B-Biology. 33: 137-142, 1996 .
104. Effects of taurine on GABA release from synaptosomes of rat olfactory
bulb.
Kamisaki Y, Wada K, Nakamoto K, Itoh T.
Amino Acids. 10: 49-57, 1996.
105. Release of taurine and its effects on release of neurotransmitter
amino acids in rat cerebral cortex.
Kamisaki Y, Wada K, Nakamoto K, Itoh T.
Advances in Experimental Medicine and Biology. 403: 445-454, 1996.
106. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying
hepatocellular carcinoma.
Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Itoh T, Kawasaki H.
Journal of Cancer Research and Clinical Oncology. 122: 585-589, 1996.
107. Protective effect of cystathionine on acute gastric mucosal injury
induced ischemia-reperfusion in rats.
Wada K, Kamisaki Y, Kitano M, Nakamoto K, Itoh T.
European Journal of Pharmacology. 294: 377-382, 1995 .
108. Direct measurement of superoxide dependent chemiluminescence from
the rat skin following UV-dependent
fluoroquinolone-induced dermatitis.
Wada K, Saniabadi AR, Umemura K, Nakano M, Ito T, Nakashima M.
Free Radical Biology and Medicine. 18: 923-927, 1995.
109. Antithrombotic effect of a new glycoprotein IIb/IIIa antagonist, SC-52012A:
Studies in two guinea pig thrombosis model.
Nishiyama H, Umemura K, Wada K, Nakashima M.
Platelets. 6: 283-287, 1995.
110. Comparison of antithrombotic effects of GPIIb/IIIa receptor antagonist
and TXA2 receptor antagonist in the guinea-pig
thrombosis model: Possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y, Asai F, Wada K, Nakashima M.
Thrombosis & Haemostasis. 73: 683-688, 1995.
111. Antithrombotic effect of a novel recombinant hirudin analogue, CX-397,
in a rat arterial thrombosis model.
Takiguchi Y, Asai F, Wada K, Hayashi H, Nakashima M.
British Journal of Pharmacology. 116: 3056-3060, 1995.
112. Nitric oxide regulates substance P release from rat spinal cord synaptosomes.
Kamisaki Y, Nakamoto K, Wada K, Itoh T.
Journal of Neurochemistry. 65: 2050-2056, 1995.
113. Nitric oxide inhibition of the depolarization-evoked glutamate release
from synaptosomes of rat cerebellum.
Kamisaki Y, Wada K, Nakamoto K, Itoh T.
Neuroscience Letters. 194: 5-8, 1995.
114. UV-dependent quinolone-induced human erythrocyte membrane lipid peroxidation:
Studies on the phototoxicity of
Y-26611, a new quinolone derivative.
Wada K, Saniabadi AR, Umemura K, Takiguchi Y, Nakashima M.
Basic & Clinical Pharmacology & Toxicology (旧: Pharmacology and Toxicology). 74: 240-243, 1994 .
115. Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F, in
the rat middle cerebral artery occlusion model.
Umemura K, Wada K, Uematsu T, Mizuno A, Nakashima M.
European Journal of Pharmacology. 251: 69-74., 1994.
116. Changes in platelet aggregation in whole blood, plasma and washed
platelets in streptozotocin-induced diabetic rats:
Time-dependent change in antiaggregatory activity of diabetic rat plasma.
Wada K, Takiguchi Y, Nakashima M.
Platelets. 4: 280-284, 1993.
117. Role of platelet-activating factor,thromboxaneA2,ADP and thrombin
in thrombogenesis in the guinea pig.
Hirata Y, Takiguchi Y, Wada K, Matsuno H, Umemura K, Uematsu T, Nakashima M.
European Journal of Pharmacology. 231: 421-425, 1993.
118. Hemodynamic effects on thrombogenesis and platelet aggregation in
spontaneously hypertensive rats.
Takiguchi Y, Wada K, Nakashima M.
Clinical and Experimental Hypertension. 15: 197-208, 1993.
119. Changes in plasma and urinary 11-dehydrothromboxane B2 in healthy
subjects produced by oral CS-518,
a novel thromboxane synthase inhibitor.
Uematsu T, Takasaki W, Kosuge K, Wada K, Matsuno H, Tanaka Y, Yamamura N, Nakashima M.
European Journal of Clinical Pharmacology. 45: 283-286, 1993 .
120. Evaluation of the combination of a tissue-type plasminogen activator,
SUN9216, and a thromboxane A2 receptor
antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
Umemura K, Wada K, Uematsu T, Nakashima M.
Stroke. 24: 1077-1082, 1993.
121. (Tetrahydro-2-furanyl)-5-fluorouracil (Ftorafur) determined in rat
hair as an index of drug exposure.
Uematsu T, Miyazawa, N, Wada K.
Journal of Pharmaceutical Sciences. 82: 1272-1274, 1993.
122. Comparison of the inhibitory effects of the TXA2 receptor antagonist,
vapiprost, and other antiplatelet drugs
on arterial thrombosis in rats: Possible role of TXA2.
Takiguchi Y, Wada K, Nakashima M.
Thrombosis Haemostasis. 68: 460-463, 1992.
123. Effect of aldose reductase inhibitor on the inhibition of platelet
aggregation induced by diabetic rat plasma.
Takiguchi Y, Wada K, Nakashima M.
European Journal of Pharmacology. 215: 289-291, 1992 .
124. Effects of vapiprost, a novel thromboxane receptor antagonist, on
thrombus formation and vascular potency
after thrombolysis by tissue-type plasminogen activator.
Matsuno H, Uematsu T, Umemura K, Takiguchi Y, Wada K, Nakashima M.
British Journal of Pharmacology. 106: 533-538, 1992.
125. Arterial thrombosis model with photochemical reaction in guinea-pig
and its property.
Takiguchi Y, Hirata Y, Wada K, Nakashima M.
Thrombosis Research. 67: 435-445, 1992.
126. Effect of diabetes on photochemically induced thrombosis in femoral
artery and platelet aggregation in rats.
Takiguchi Y, Wada K, Matsuno H, Nakashima M.
Thrombosis Research. 63: 445-456, 1991 .
127. Effect of tiopronin on prostaglandin synthesis in rabbit kidney medulla
slices.
Fujita T, Fujimoto Y, Wada K, Kaneko M, Sakuma S, Iso T.
Journal of Pharmacy and Pharmacology. 40: 650-651, 1988.
128. Effect of angiotensin-converting enzyme inhibitor YS980 on prostaglandin
synthesis in rabbit kidney medulla slices.
Fujimoto Y, Wada K, Kaneko M, Fujita T.
British Journal of Pharmacology. 92: 479-481, 1987.
欧文総説
1. Microbiota and nonalcoholic steatohepatitis. .
Imajo K, Yoneda M, Ogawa Y, Wada K, Nakajima A.
Seminars in Immunopathology. 36: 115-132, 2014.
2. Rodent models of nonalcoholic Fatty liver disease/nonalcoholic steatohepatitis.
Imajo K, Yoneda M, Kessoku T, Ogawa Y, Maeda S, Sumida Y, Hyogo H, Eguchi
Y, Wada K, Nakajima A.
International Journal of Molecular Sciences. 14: 21833-21857, 2013.
3. Novel situations of endothelial injury on stroke: novel mechanisms on
strategy of drug development.
Umemura K, Wada K.
Journal of Pharmacological Sciences. 116: 18-19, 2011.
4. Novel findings for the development of drug therapy for various liver
diseases: Liver microsomal triglyceride transfer
protein activator may be a possible therapeutic agent in non-alcoholic
steatohepatitis.
Fujita K, Imajyo K, Shinohara Y, Nozaki Y, Wada K, Yoneda M, Endo H, Takahashi H, Abe Y, Inamori M,
Shimamura T, Kobayashi N, Kirikoshi H, Kubota K, Saito S, Nakajima A.
Journal of Pharmacological Sciences. 115: 270-273, 2011.
5. Novel findings for the development of drug therapy for various liver
diseases.
Yoneda M, Nakajima A, Wada K.
Journal of Pharmacological Sciences. 115: 259-262, 2011.
6. Molecular mechanisms linking adiponectin receptor signaling and cancer.
Nakajima A, Endo H, Yoneda K, Fujisawa T, Sugiyama M, Hosono K, Nozaki
Y, Takahashi H, Fujita K, Yoneda M,
Inamori M, Shimamura T, Kobayashi N, Kirikoshi H, Kubota K, Saito S,
Wada K, Nakagama H.
The Open Obesity Journal. 2: 43-49, 2010.
7. Involvement of P. gingivalis on the development of human aortic aneurysm.
Wada K, Kamisaki Y.
Journal of Pharmacological Sciences. 113: 115-119, 2010.
8. : Roles of oral bacteria on cardiovascular diseases -Molecular mechanisms
to clinical cases-
Umemura K, Wada K.
Journal of Pharmacological Sciences. 113: 101-102, 2010.
9. Molecular dissection of Porphyromonas gingivalis-related arteriosclerosis:
A novel mechanism of vascular disease.
Wada K, Kamisaki Y.
Periodontology 2000. 54: 222-234, 2010.
10. Gene expression in nonalcoholic steatohepatitis patients and treatment
strategies.
Yoneda M, Endo H, Nozaki Y, Tomimoto A, Fujisawa T, Fujita K, Yoneda
K, Takahashi H, Saito S, Iwasaki T,
Yamamoto S, Tsutsumi S, Aburatani H, Wada K, Hotta K, Nakajima A.
Journal of Pharmacological Sciences. 105: 151-156, 2007.
11. Endocrine disruptors stimulate lipid accumulation in target cells related
to metabolic syndrome.
Wada K, Sakamoto H, Nishikawa K, Sakuma S, Nakajima A, Fujimoto Y, Kamisaki Y.
Journal of Pharmacological Sciences. 105: 133-137, 2007.
12. Life style-related diseases of the digestive system: from molecular
mechanisms to therapeutic strategies.
Nakajima A, Wada K.
Journal of Pharmacological Sciences. 105: 127-128, 2007.
13. Nuclear receptors on stem cells: The role of nuclear receptors during
neural stem cell proliferation and differentiation.
Katayama K, Wada K, Nakajima A, Kamisaki Y.
Journal of Pharmacological Sciences. 97: 171-176, 2005.
14. Nuclear receptors on diseases; Nuclear receptors as targets for drug
development.
Nakajima A, Wada K.
Journal of Pharmacological Sciences. 97: 163-163, 2005.
15. Protective effects of PPARγ in gastrointestinal mucosal injuries.
Matsuhashi N, Nakajima A, Wada K, Miki H, Saubermann LJ, Kubota N, Terauchi Y, Kadowaki T, Nagai R,
Blumberg RS.
Recent Research Developments in Immunology. 4: 227-233, 2002.
16. PPARγ and inflammatory bowel disease: A new therapeutic target for
ulcerative colitis and Crohn’s disease.
Wada K, Nakajima A, Blumberg RS.
Trends in Molecular Medicine. 7: 329-331, 2001.